Compare AstraZeneca plc (AZN) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Quantum Computing Inc — how do they compare? AstraZeneca plc trades at $169.19 (market cap $253.13B), while Quantum Computing Inc trades at $8.01 (market cap $1.88B). The key difference: AstraZeneca plc is far larger — about 134.6× Quantum Computing Inc's market cap, and AstraZeneca plc pays a 1.92% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals.
| AZN | QUBT | |
|---|---|---|
Market Cap | $253.13B | $1.88B |
Sector | Health | Technology |
52-Week High | $209.48 | $24.62 |
52-Week Low | $137.44 | $6.31 |
Enterprise Value | $279.37B | $894.04M |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Quantum Computing Inc. (QUBT) trades at $8.00, down 7.62% amid sector-wide selling pressure. The stock shows bearish technical signals with negative moving averages but oversold RSI readings. Fundamentally, the company reported a net loss of $18.67 million on minimal revenue of $682,000 in 2025, though it maintains strong analyst support with a $24.00 consensus price target representing 200% upside potential. Recent strategic acquisitions and commercial agreements highlight growth initiatives.
QUBT presents high-risk, high-reward potential with significant cash burn offset by promising technology positioning. The company's photonics-based quantum approach and government policy support provide growth catalysts, but profitability remains distant with negative margins. Investors face substantial execution risk amid competitive quantum computing landscape, though analyst consensus remains strongly bullish on long-term prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
